AQUAPASS Receives Marketing Approval in Israel, Enabling Access to Novel Therapy for Patients with Fluid Overload

NEWTON, Mass. and SHEFAYIM, Israel, Dec. 8, 2025 /PRNewswire/ -- AQUAPASS, a medical technology company pioneering non-invasive fluid management solutions, has received marketing approval for the AQUAPASS System in Israel, marking a major milestone in bringing its novel therapy to patients suffering from fluid overload.

As part of the initial rollout, AQUAPASS will begin commercial deployment in selected medical centers across Israel, working closely with leading clinicians to collect clinical feedback and develop real-world evidence that will support broader adoption and long-term integration into patient care.

The ongoing FDA pivotal REFORM-HF (NCT06360380) trial, enrolling at hospitals in both the U.S. and Israel, continues. REFORM-HF is evaluating Net Fluid Loss with and without the